NCT04109924 2026-02-10TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO StudyRoswell Park Cancer InstitutePhase 2 Completed42 enrolled 12 charts